VWM
ASBP

Valley Wealth Managers’s Aspire Biopharma ASBP Stock Holding History

Valley Wealth Managers’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03K Hold
33
– – ﹤0.01% 295
2025
Q4 		$5.28K Hold
33
– – ﹤0.01% 305
2025
Q3 		$8.24K Hold
33
– – ﹤0.01% 269
2025
Q2 		$10.8K Buy
+33
New +$15.7K ﹤0.01% 245

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Valley Wealth Managers's ASBP Position: Q1 2026 in Review

Valley Wealth Managers held its Aspire Biopharma (ASBP) position steady in Q1 2026 at 33 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #295.

Valley Wealth Managers first reported a position in ASBP in Q2 2025 and has held it in 4 quarters since. The position peaked at $10.8K in Q2 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Valley Wealth Managers held 33 shares of Aspire Biopharma worth $1.03K as of Q1 2026.
  • Valley Wealth Managers left its Aspire Biopharma share count unchanged in Q1 2026.
  • Aspire Biopharma made up ﹤0.01% of Valley Wealth Managers's portfolio in Q1 2026, its #295 holding.
  • Valley Wealth Managers first reported a position in Aspire Biopharma in Q2 2025 and has held it in 4 quarters since.
  • Valley Wealth Managers's Aspire Biopharma position peaked at $10.8K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Valley Wealth Managers's 13F filing for Q1 2026, filed 6 May 2026.